ENOXAPARIN: Clinical Overview
Enoxaparin is a low-molecular-weight heparin (LMWH) indicated for venous thromboembolism (VTE) prophylaxis and treatment, as well as anticoagulation in acute coronary syndromes (ACS), with specific dosing regimens that vary by clinical indication, patient weight, renal function, and age.
Primary Indications
1. Acute Coronary Syndromes (ACS)
For NSTE-ACS initial therapy: 1 mg/kg subcutaneous every 12 hours 1. This represents the standard approach for patients managed either conservatively or with planned invasive strategy.
For STEMI with fibrinolytic therapy: The dosing differs significantly by age 1, 2:
- Age <75 years: 30 mg IV bolus, followed in 15 minutes by 1 mg/kg subcutaneous every 12 hours (maximum 100 mg for first 2 doses)
- Age ≥75 years: NO bolus; 0.75 mg/kg subcutaneous every 12 hours (maximum 75 mg for first 2 doses)
To support PCI: Dosing depends on prior enoxaparin administration 1, 3:
- If last subcutaneous dose was within 8 hours: give NO additional enoxaparin
- If last dose was 8-12 hours earlier OR only 1 dose given: administer 0.3 mg/kg IV
- If no prior anticoagulant therapy: 0.5-0.75 mg/kg IV bolus
2. VTE Prophylaxis
Hospitalized medical patients: 40 mg subcutaneous once daily for duration of hospital stay or until fully ambulatory 4, 5.
Surgical patients: Two acceptable regimens 4, 5:
- 40 mg given 2-4 hours preoperatively, then 40 mg once daily thereafter
- 40 mg given 10-12 hours preoperatively, then 40 mg once daily thereafter
Duration: minimum 7-10 days; consider extended prophylaxis up to 4 weeks for high-risk patients 4, 5.
Outpatient cancer patients: 40 mg subcutaneous once daily 4. This applies to ambulatory cancer patients receiving chemotherapy with high VTE risk.
3. VTE Treatment
Initial therapy: Two dosing options 4, 5:
- 1 mg/kg subcutaneous every 12 hours
- 1.5 mg/kg subcutaneous once daily
Long-term therapy in cancer patients: 4, 5
- 200 IU/kg (approximately 1.5 mg/kg) once daily for 1 month, then continue at same dose
- Alternative: 1.5 mg/kg once daily or 1 mg/kg every 12 hours
The once-daily dosing provides convenience, though some evidence suggests twice-daily dosing may be more efficacious for enoxaparin specifically 5.
Critical Dosing Adjustments
Renal Impairment (CrCl <30 mL/min)
This is a crucial adjustment that prevents drug accumulation and bleeding:
- ACS: Reduce to 1 mg/kg subcutaneous once daily (every 24 hours) 1, 2
- VTE treatment: Reduce to 1 mg/kg subcutaneous once daily 4, 5
- VTE prophylaxis: Some sources suggest avoiding enoxaparin entirely when CrCl <30 mL/min or using anti-factor Xa monitoring 5, 6
Important caveat: The 2018 ASH guidelines suggest AGAINST routine anti-factor Xa monitoring even in renal dysfunction, recommending instead to use renally-adjusted doses per product labeling or switch to unfractionated heparin 6. This represents a practical approach given the lack of evidence that monitoring improves outcomes.
Obesity
For VTE prophylaxis in morbidly obese patients (particularly post-cesarean): Consider intermediate dosing of 40 mg subcutaneous every 12 hours rather than standard 40 mg once daily 7. Weight-based dosing of 0.5 mg/kg every 12 hours achieves more consistent prophylactic anti-Xa levels 7.
For trauma patients: Weight-based dosing of 0.5 mg/kg every 12 hours (max 60 mg) achieves goal prophylactic levels in 66.5% of patients versus only 42.8% with fixed 30 mg twice daily 8.
Pregnancy and Postpartum
Recommended as preferred agent over unfractionated heparin due to better bioavailability, longer half-life, more predictable effect, and lower risk of heparin-induced thrombocytopenia and osteopenia 7.
Standard prophylactic dose: 40 mg subcutaneous once daily 7
Timing after neuraxial anesthesia (critical for preventing spinal hematoma): 7
- Prophylactic doses (40 mg daily): May start 4 hours after catheter removal but NOT earlier than 12 hours after block performed
- Intermediate doses (40 mg every 12 hours): May start 4 hours after catheter removal but NOT earlier than 24 hours after block performed
Contraindications
Absolute contraindications:
- Active major bleeding
- Severe thrombocytopenia (platelet count <50,000/mm³)
- History of heparin-induced thrombocytopenia (HIT)
- Hypersensitivity to enoxaparin, heparin, or pork products
Relative contraindications requiring careful assessment:
- Recent neurosurgery or spinal procedures
- Uncontrolled severe hypertension
- Bacterial endocarditis
- Severe hepatic dysfunction with coagulopathy
Monitoring Considerations
Routine monitoring is NOT required for most patients, which represents a major advantage over unfractionated heparin 6.
Consider anti-factor Xa monitoring in specific situations:
- Severe renal impairment (though ASH guidelines suggest against routine monitoring even here) 6
- Extremes of body weight (<50 kg or >150 kg)
- Pregnancy (controversial; not universally recommended)
- Therapeutic dosing in high-risk situations
Goal anti-factor Xa levels:
- Prophylaxis: 0.2-0.4 IU/mL (peak, 4 hours post-dose)
- Treatment: 0.5-1.0 IU/mL for twice-daily dosing; 1.0-2.0 IU/mL for once-daily dosing
Platelet monitoring: Check baseline and periodically (every 2-3 days during first 2 weeks) to detect heparin-induced thrombocytopenia, though risk is lower than with unfractionated heparin.
Common Pitfalls and Caveats
Do NOT switch between enoxaparin and unfractionated heparin during treatment course—this increases bleeding risk 2, 3.
Timing matters for PCI: The 8-hour window is critical. Giving additional enoxaparin when the last dose was <8 hours ago increases bleeding without benefit 1, 3.
Age-based dosing in STEMI with fibrinolytics: The elimination of the IV bolus in patients ≥75 years is evidence-based and reduces bleeding risk 1, 2, 3.
Renal function assessment: Use Cockcroft-Gault formula for creatinine clearance calculation, not eGFR, as this is what was used in clinical trials 3.
Cancer patients require extended therapy: Unlike non-cancer patients who typically receive 3-6 months of anticoagulation, cancer patients benefit from indefinite anticoagulation or at least duration of active cancer treatment 4, 5.
Neuraxial anesthesia timing: The specific time intervals (12 hours for prophylactic, 24 hours for therapeutic dosing) are based on pharmacokinetic data and must be strictly observed to prevent catastrophic spinal hematomas 7, 5, 7.